These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16294173)

  • 1. [Pulmonary arterial hypertension].
    Chaouat A; Dinh-Xuan AT
    Rev Mal Respir; 2005 Sep; 22(4):567-8. PubMed ID: 16294173
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience and reason.
    Barst RJ
    Chest; 2000 Jan; 117(1):2-5. PubMed ID: 10631187
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary hypertension--beyond vasodilator therapy.
    Fishman AP
    N Engl J Med; 1998 Jan; 338(5):321-2. PubMed ID: 9445414
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in prostacyclin therapy for pulmonary arterial hypertension.
    Eells PL
    Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary hypertension update.
    Hesselgrave B
    Case Manager; 2005; 16(6):61-6; quiz 67. PubMed ID: 16326325
    [No Abstract]   [Full Text] [Related]  

  • 7. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
    Rafanan AL; Maurer J; Mehta AC; Schilz R
    Chest; 2000 Nov; 118(5):1497-500. PubMed ID: 11083710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic pulmonary arterial hypertension in children.
    Rosenzweig EB; Barst RJ
    Curr Opin Pediatr; 2005 Jun; 17(3):372-80. PubMed ID: 15891429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous intravenous prostacyclin for advanced primary pulmonary hypertension.
    Archer-Chicko C
    Dimens Crit Care Nurs; 2000; 19(2):14-21. PubMed ID: 10876492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
    Ogawa A; Miyaji K; Yamadori I; Shinno Y; Miura A; Kusano KF; Ito H; Date H; Matsubara H
    Circ J; 2012; 76(7):1729-36. PubMed ID: 22481098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
    Robbins IM; Gaine SP; Schilz R; Tapson VF; Rubin LJ; Loyd JE
    Chest; 2000 Jan; 117(1):14-8. PubMed ID: 10631192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy for pulmonary arterial hypertension: what's on the menu today?
    Mehta S
    Chest; 2003 Dec; 124(6):2045-9. PubMed ID: 14665473
    [No Abstract]   [Full Text] [Related]  

  • 13. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
    Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
    Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timeline of haemodynamic improvement with subcutaneous prostacyclin therapy in a patient with severe pulmonary arterial hypertension.
    Sadushi-Koliçi R; Perthold W; Fruhwald FM; Lang IM
    Eur J Clin Invest; 2008 Aug; 38(8):603-4. PubMed ID: 18573098
    [No Abstract]   [Full Text] [Related]  

  • 15. Dose-dependent reduction in pulmonary vascular resistance with epoprostenol in pulmonary arterial hypertension.
    Homma S
    Circ J; 2010 Oct; 74(10):2062-3. PubMed ID: 20838003
    [No Abstract]   [Full Text] [Related]  

  • 16. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension.
    Park MH; Scott RL; Uber PA; Ventura HO; Mehra MR
    Congest Heart Fail; 2004; 10(5):221-5. PubMed ID: 15470298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current issues in pulmonary hypertension].
    Forster T
    Orv Hetil; 2012 Apr; 153(16):603-6. PubMed ID: 22510315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
    Park MH
    Catheter Cardiovasc Interv; 2008 Feb; 71(2):205-13. PubMed ID: 18327839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 20. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.